KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update [Yahoo! Finance]
KalVista Pharmaceuticals, Inc. (KALV)
Last kalvista pharmaceuticals, inc. earnings: 3/10 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.kalvista.com
Company Research
Source: Yahoo! Finance
–Multinational regulatory submissions for sebetralstat position Company to transform hereditary angioedema (HAE) treatment worldwide– –Pro forma cash and cash equivalents of $292.2 million provide runway into second half 2027– CAMBRIDGE, Mass. & SALISBURY, England, December 05, 2024 BUSINESS WIRE )--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today released financial results for the second fiscal quarter ended October 31, 2024. The Company also provided an operational update, highlighted by the U.S. Food and Drug Administration (FDA) acceptance of a New Drug Application (NDA) for sebetralstat, a novel, investigational treatment for hereditary angioedema (HAE). "KalVista is successfully executing on the key milestones we announced at the beginning of our fiscal year as we move towards multiple potential commercial launches of sebetralstat in 2025," said Ben Palleiko, Chief Executive Officer of KalVista. "With six marketing authorization applications filed to date and the firs
Show less
Read more
Impact Snapshot
Event Time:
KALV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KALV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KALV alerts
High impacting KalVista Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
KALV
News
- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) is now covered by analysts at Bank of America Co.. They set a "buy" rating and a $22.00 price target on the stock.MarketBeat
- KalVista Appoints Jeb Ledell as Chief Operating Officer [Yahoo! Finance]Yahoo! Finance
- KalVista Appoints Jeb Ledell as Chief Operating OfficerBusiness Wire
- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
KALV
Earnings
- 12/5/24 - Beat
KALV
Sec Filings
- 12/16/24 - Form 8-K
- 12/9/24 - Form 4
- 12/5/24 - Form 8-K
- KALV's page on the SEC website